Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC Conditioned Medium for Chronic Ulcer Wounds
NCT04134676Phase 1Completed
- Sponsor
- Sukma Skin Treatment
- Start
- Jun 2019
- Primary completion
- May 2020
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium in chronic skin ulcer, sponsored by Sukma Skin Treatment. Primary endpoint: Success rate of chronic ulcer healing at 2 weeks. Started Jun 2019; status: completed.
02
Drugs
Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium
03
Conditions
chronic skin ulcer
Beyond the preview
Go deeper on NCT04134676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134676.